This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| DER-CE | |
|---|---|
| Name | DER-CE |
| Type | Medical device / intervention |
| Inventor | Unknown |
| Developer | Multiple institutions |
| Introduced | 21st century |
| Status | Investigational / Approved in select jurisdictions |
DER-CE
DER-CE is a medical intervention platform combining device-mediated energy delivery with targeted cellular engineering for tissue regeneration and modulation. It integrates modalities from interventional radiology, biomedical engineering, and regenerative medicine to address structural and functional disorders across multiple organ systems. DER-CE has been evaluated in preclinical models and clinical trials coordinated by academic centers, regulatory agencies, and industry partners.
DER-CE denotes a composite technology that merges device energy resonance (DER) and cellular enhancement (CE) modalities; terminology appears in publications from institutions such as Mayo Clinic, Johns Hopkins Hospital, Cleveland Clinic, and Massachusetts General Hospital. Related nomenclature appears alongside projects from National Institutes of Health, European Medicines Agency, Food and Drug Administration (United States), and consortia including Wellcome Trust-funded programs. Comparative terminology is used in literature involving Harvard Medical School, Stanford University School of Medicine, Karolinska Institutet, Imperial College London, and University College London. In regulatory filings, DER-CE is often categorized with other technologies from Medtronic, Boston Scientific, Medtronic plc, Abbott Laboratories, and Stryker Corporation.
Early conceptual roots trace to work at Massachusetts Institute of Technology and California Institute of Technology integrating energy delivery research from Bell Labs and cellular manipulation methods from Cold Spring Harbor Laboratory. Seminal projects involved collaborations between NIH branches, including National Institute of Biomedical Imaging and Bioengineering and National Heart, Lung, and Blood Institute, and academic spinouts from MIT Media Lab and Wyss Institute. Pilot clinical research teams at Mount Sinai Hospital, UCLA Health, Duke University Hospital, and Vanderbilt University Medical Center executed first-in-human studies. Funding and translational support were provided by agencies such as Horizon 2020, European Commission, Bill & Melinda Gates Foundation, and corporate partners like Johnson & Johnson. Key milestones involved presentations at meetings hosted by American College of Cardiology, European Society of Cardiology, American Society of Clinical Oncology, Radiological Society of North America, and American Academy of Neurology.
DER-CE systems typically combine hardware from companies like Siemens Healthineers, GE Healthcare, and Philips Healthcare with biologic components derived from protocols at Salk Institute for Biological Studies, The Rockefeller University, and Scripps Research. Mechanisms build on technologies such as radiofrequency ablation used in Medtronic devices, focused ultrasound approaches from Insightec, and electroporation techniques developed in collaboration with EP Systems and academic labs at Johns Hopkins University. Cellular engineering elements draw on methods from CRISPR-Cas9 research at Broad Institute, gene delivery vectors studied at Addgene, and stem cell protocols from National Stem Cell Foundation. Control systems use algorithms influenced by work at Google DeepMind, IBM Research, and Microsoft Research for adaptive dosing, while imaging guidance employs modalities refined at Mayo Clinic and UCSF Medical Center.
Clinical trials have explored DER-CE in contexts including cardiovascular repair at Cleveland Clinic and Brigham and Women's Hospital, neurorestoration pursued at Massachusetts General Hospital and Johns Hopkins Hospital, oncologic ablation studied at MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center, and musculoskeletal regeneration trials at Hospital for Special Surgery and Mayo Clinic. Indications under study parallel those addressed by devices from Cook Medical and biologics from Amgen, such as myocardial ischemia, focal epilepsy, liver tumors, and osteochondral defects. Multidisciplinary care teams from Rochester General Hospital, Toronto General Hospital, and Singapore General Hospital have enrolled patients in registries to evaluate real-world outcomes.
Safety assessments reference standards from International Organization for Standardization committees, ISO guidelines, and reporting frameworks used by World Health Organization collaborations. Efficacy endpoints align with outcome measures from trials coordinated by groups including ClinicalTrials.gov-registered networks, European Society for Medical Oncology, and American Heart Association-led consortia. Published outcome data have been presented at conferences such as American Society of Clinical Oncology Annual Meeting, American College of Cardiology Scientific Session, and European Congress of Radiology. Comparative effectiveness analyses draw on registries maintained by Society of Thoracic Surgeons and National Surgical Quality Improvement Program.
Regulatory pathways involve interactions with Food and Drug Administration (United States), European Medicines Agency, Medicines and Healthcare products Regulatory Agency (UK), Health Canada, and Therapeutic Goods Administration (Australia). Guidance documents reference standards from International Electrotechnical Commission, ISO 13485, and premarket submissions analogous to devices cleared by FDA 510(k) and CE marking processes. Professional society guidance from American College of Radiology, European Society of Cardiology, and American Academy of Neurology informs clinical use algorithms and consensus statements.
Ongoing research bridges teams at Broad Institute, Cold Spring Harbor Laboratory, Francis Crick Institute, Max Planck Institute for Medical Research, and RIKEN exploring integration with immunotherapy advances pioneered at Dana-Farber Cancer Institute and Fred Hutchinson Cancer Center. Innovations include combining DER-CE with biomaterials developed at ETH Zurich and École Polytechnique Fédérale de Lausanne, AI-driven treatment planning from Carnegie Mellon University collaborations, and multicenter trials coordinated by International Committee of the Red Cross-affiliated research networks. Emerging translational efforts involve partnerships with startups incubated at Y Combinator and venture groups such as Sequoia Capital and Andreessen Horowitz.